|
 |
| |
|
Erythromycin Breath Test Reproducibility
|
 |
|
|
In House Studies
Metabolic Solutions has conducted Erythromycin Breath Test
reproducibility studies in 25 subjects (ages 18-65).
The two tests were conducted separately between 24 to
72 hours later. The following percent erythromycin
metabolized per hour results were observed: |
| |
Test 1 |
Test 2 |
Relative Standard Deviation |
| Mean (N=25) |
1.91 |
1.92 |
8.82 |
| Std Deviation |
0.34 |
0.34 |
8.94 |
|
Thus, the Erythromycin Breath Test has an intrasubject
variability of less than 10%.
Published Studies
Gharaibeh et al., (1998) Effect of
multiple doses of rifampin on the [14C N-methyl]
erythromycin breath test in healthly male volunteers.
J. Clin. Pharmacol. 38:492-495.
"The intrasubject variability of the EBT performed
on different days (arithmetric difference of day -4
and day 1 EBT values) was low and ranged from 0.04 to
0.61% 14CO2/hr." The
intrasubject variability in 8 subjects was 13%.
McCrea et al. (1999) Concurrent
administration of the erythromycin breath test (EBT)
and oral midazolam as in vivo probes for CYP3A activity.
J. Clin. Pharmacol. 39:1212-1220.
"Twelve males received the probes in a two-period
crossover fashion; one period included the probes on
two occasions, 5 days apart. The within-subject
CV for the EBT (% 14CO2/hr) and
midazolam AUC was 4.9% and 16.9% respectively.
Concurrent administration of the EBT and oral midazolam
is a sensitive and reproducible tool to screen new chemical
entities for potentially important CYP3A interactions."
|
Metabolic Solutions, Inc., 460
Amherst Street, Nashua, NH 03063
Privacy
Policy
|
|
|
